59 results
8-K
EX-99.2
SQZB
SQZ Biotechnologies Co
13 Sep 21
SQZ Biotechnologies Announces First Autoimmune Disease Indication
6:53am
are taking to discover and develop product candidates and whether it will lead to marketable products; the expense, time‐consuming nature and uncertainty … T Cell Infiltration as a Prognostic Indicator in Solid Tumors PC Tumeh et. al. Nature. 2014 Responders Progressors Balermpas, et. Al. British Journal
8-K
EX-10.1
SQZB
SQZ Biotechnologies Co
7 Jul 23
Departure of Directors or Certain Officers
4:30pm
(Parachute Payments) of the Employment Agreement, if applicable.
This letter is not intended to and does not change in any way the at-will nature
8-K
EX-99.2
SQZB
SQZ Biotechnologies Co
4 Jun 21
Regulation FD Disclosure
8:09am
to marketable products; the expense, time-consuming nature and uncertainty of clinical trials; enrollment and retention of patients; potential side effects of our … antigen presentation SQZ APCs SQZ eAPCs SQZ AACs PC Tumeh et. al. Nature. 2014 Responders Progressors Strong Correlation of CD8 TILs with Clinical
S-1
EX-10.11
SQZB
SQZ Biotechnologies Co
9 Oct 20
IPO registration
4:59pm
in the future, the at-will nature of your employment may not be changed, except in a subsequent letter or written agreement, signed by you and a duly
S-1
EX-4.3
SQZB
SQZ Biotechnologies Co
9 Oct 20
IPO registration
4:59pm
a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration … upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares
S-1
EX-10.10
3e3wsml
9 Oct 20
IPO registration
4:59pm
8-K
EX-99.3
en8mxe lj
9 Dec 21
Other Events
7:30am
D
372gi2 or
3 Apr 14
$1M in equity, sold $15K, 1 investor
12:00am
8-K
EX-2.1
rl8py0k8u mq6kntm5yn
22 Dec 23
Entry into a Material Definitive Agreement
5:18pm
D
ky84g u3n
25 Nov 19
Indefinite amount in equity, sold $71.25M, 48 investors
10:05am
D
6yfmvw0b
1 Jun 20
$70.2M in equity, sold $66.25M, 27 investors
12:01pm
DRS/A
EX-10.9
rpyjzc3qcef
28 Aug 20
Draft registration statement (amended)
12:00am
S-1
EX-10.9
es23s6zl3oak5 29h6
9 Oct 20
IPO registration
4:59pm
S-1/A
EX-10.6
btn7ez xv1783
26 Oct 20
IPO registration (amended)
6:33am
PREM14A
h5ily01
12 Jan 24
Preliminary proxy related to merger
8:57am
DEFM14A
bztmjhhc z9bxfiii
23 Jan 24
Proxy related to merger
4:31pm
CORRESP
g0kj1w6a3
14 Oct 20
Correspondence with SEC
12:00am
S-1/A
EX-3.3
orzq 920sf9pk
26 Oct 20
IPO registration (amended)
6:33am
S-8
EX-4.3
trwoxla6zgi
30 Oct 20
Registration of securities for employees
5:12pm